Microbiome-Based Deal Benchmarks in Gastroenterology
Market Analysis
Microbiome-Based therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 microbiome-based asset in gastroenterology is $401M, with total deal values reaching $2.0B. Development milestones average $344M, while regulatory milestones contribute $410M.
The gastroenterology microbiome-based landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for microbiome-based gastroenterology deals range from 7% to 13.1% at the base tier, with tiered escalation reaching 11%-17.1% on blockbuster sales. Commercial milestones averaging $886M further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a microbiome-based gastroenterology licensing deal?
What is the total deal value for microbiome-based gastroenterology transactions?
What royalty rates are standard for microbiome-based deals in gastroenterology?
How are milestones structured in microbiome-based gastroenterology deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.